These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1482 related items for PubMed ID: 19751116
1. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study. Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel. Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116 [Abstract] [Full Text] [Related]
2. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Valensi P, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Wenying Y, IMPROVE Study Group Expert Panel. Int J Clin Pract; 2009 Mar; 63(3):522-31. PubMed ID: 19187170 [Abstract] [Full Text] [Related]
3. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study. Gao Y, Guo XH, Vaz JA, PRESENT Study Group. Diabetes Obes Metab; 2009 Jan; 11(1):33-40. PubMed ID: 18494806 [Abstract] [Full Text] [Related]
4. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Khutsoane D, Sharma SK, Almustafa M, Jang HC, Azar ST, Danciulescu R, Shestakova M, Ayad NM, Guler S, Bech OM, PRESENT Study Group. Diabetes Obes Metab; 2008 Mar; 10(3):212-22. PubMed ID: 18269636 [Abstract] [Full Text] [Related]
5. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Dornhorst A, Lüddeke HJ, Sreenan S, Kozlovski P, Hansen JB, Looij BJ, Meneghini L, PREDICTIVE Study Group. Int J Clin Pract; 2008 Apr; 62(4):659-65. PubMed ID: 18324957 [Abstract] [Full Text] [Related]
6. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes. Clements MR, Tits J, Kinsley BT, Råstam J, Friberg HH, Ligthelm RJ. Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638 [Abstract] [Full Text] [Related]
7. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Strojek K, Bebakar WM, Khutsoane DT, Pesic M, Smahelová A, Thomsen HF, Kalra S. Curr Med Res Opin; 2009 Dec; 25(12):2887-94. PubMed ID: 19821654 [Abstract] [Full Text] [Related]
12. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA, Orals Plus Apidra and LANTUS (OPAL) study group. Diabetes Obes Metab; 2008 Dec; 10(12):1178-85. PubMed ID: 19040645 [Abstract] [Full Text] [Related]
13. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes. Ligthelm RJ, Mouritzen U, Lynggaard H, Landin-Olsson M, Fox C, le Devehat C, Romero E, Liebl A. Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):511-9. PubMed ID: 17115349 [Abstract] [Full Text] [Related]
14. An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes. Dashora U, Ashwell SG, Home PD. Diabetes Obes Metab; 2009 Jul; 11(7):680-7. PubMed ID: 19527481 [Abstract] [Full Text] [Related]
15. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. Shestakova M, Sharma SK, Almustafa M, Min KW, Ayad N, Azar ST, Danciulescu R, Khutsoane D, Guler S. Curr Med Res Opin; 2007 Dec; 23(12):3209-14. PubMed ID: 18005503 [Abstract] [Full Text] [Related]
16. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes. Bebakar WM, Chow CC, Kadir KA, Suwanwalaikorn S, Vaz JA, Bech OM, BIAsp-3021 study group. Diabetes Obes Metab; 2007 Sep; 9(5):724-32. PubMed ID: 17593237 [Abstract] [Full Text] [Related]